- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03634462
Complete Decongestive Therapy With Negative Pressure for Lipedema and Lymphedema Therapy
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study will assess the treatment impact of complete decongestive therapy (CDT) in conjunction with negative pressure application using PhysioTouch (R) in women with lipedema or secondary lymphedema. Lipedema is an adipose tissue disorder in which persons experience pain and swelling in their legs and lower quadrants. Lipedema is a disorder that almost exclusively effects females, is frequently inherited, and is triggered by hormonal changes. Symptomatology includes symmetric swelling of the hypodermis of the legs, indentations in the fat causing uneven skin which may include large extruding mounds of tissue, is often accompanied by lymphedema, and is unresponsive to diet or exercise.
Women with secondary limb lymphedema in this study are persons who have developed lymphedema following cancer treatment. Persons with lymphedema or lipedema often receive CDT. CDT is a common conservative treatment to optimize lymphatic functioning using exercise, compression, lymphatic stimulation and skin care. An adjunct component of therapy is the use of gentle graded negative pressure to further enhance lymphatic stimulation. PhysioTouch is a gentle graded negative pressure device designed to enhance lymphatic stimulation.
The investigators will evaluate to what extent CDT with graded negative pressure impacts lymphatic functioning in patients with lipedema or lymphedema of the lower extremities. Additionally, the investigators will also noninvasively evaluate lymphatic function using Magnetic Resonance (MR) lymphangiography without contrast, and whether tissue sodium and fat composition are associated with reduced lymphatic pumping dynamics in the study's group cohorts. This will provide new information on the mechanism of dysfunctional fat clearance in patients with lipedema using traditional conservative therapy. By outlining internal mechanisms underlying lipedema etiology, and their response to CDT, this will provide objective markers elucidating the unique characteristics of lipedema compared with secondary lymphedema.
Study hypothesis: Therapeutic manipulation of lymphatic stasis over six weeks increases lymphatic pumping kinetics and reduces tissue sodium accumulation.
Biophysical measurements will also be acquired, including bioimpedance spectroscopy and perometry. Three cohorts will be studied: age-, gender-, and BMI-matched study controls, patients with lipedema, and patients with secondary unilateral leg lymphedema from cancer therapies. Only females will be recruited since lipedema primarily affects females. Only patients with leg lymphedema following cancer therapies will be recruited to control for the known reason for leg lymphedema. Subjects will be recruited from age 14 years and older since lipedema is triggered by hormonal changes occurring with menarche and pregnancy. Measurements will be repeated on a separate study date in a subset of volunteers. Reproducibility will be determined using an intraclass correlation coefficient; results will establish the normative range of these measures in healthy tissue. Significant differences in imaging metrics and biophysical measures between groups will be evaluated using a one-way ANOVA. This work will improve the investigators understanding of the physiology of lipedema compared to obesity and lymphedema. The results will determine the potential for these measures to serve as biomarkers of lipedema, as distinguished from obesity or on a spectrum of lymphedema. The results will also evaluate for changes in lymphatic pumping and tissue sodium accumulation following a commonly used physical therapy intervention over a course of 6 weeks in the two patient populations, lipedema (n=5) and secondary leg lymphedema (n=5).
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Tennessee
-
Nashville, Tennessee, United States, 37212
- Vanderbilt University Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Females with a diagnosis of lipedema or a probable diagnosis of lipedema
- Females with a diagnosis of secondary limb lymphedema following cancer treatments
Exclusion Criteria:
- Subjects who have any type of non-MRI compatible bioimplant activated by mechanical, electronic, or magnetic means (e.g., cochlear implants, pacemakers, neurostimulators, biostimulators, electronic infusion pumps, etc.) or are not able to comfortably be able to tolerate the limited fit of the MRI
- Subjects who have any type of ferromagnetic bioimplant that could potentially be displaced.
- Subjects who may have shrapnel imbedded in their bodies (such as from war wounds), metal workers and machinists (potential for metallic fragments in or near the eyes).
- Pregnant women will be excluded from the MRI portion of the study only
- Subjects who have open wounds on either ankle or top of foot because of contraindications with placement of electrodes to obtain the L-DEX U400 readings.
- Persons with heart pacemakers.
- Persons with Dercum's disease, diabetes or high blood pressure (systolic great than 140 and diastolic great than 90).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Patients with Lipedema
Females with lipedema who meet the inclusion and exclusion criteria for lipedema and this study requirements.
The intervention in this arm is a course of CDT with graded negative pressure.
|
Complete Decongestive Therapy (CDT)is a common conservative intervention involving stimulation of the lymphatic system, use of compression, skin care and exercise.
The use of graded negative pressure in conjunction with CDT is another conservative therapy intervention used to help clear the lymphatic congestion.
|
Experimental: Patients with secondary leg lymphedema
Patients with secondary leg lymphedema following cancer therapies will be limited to the female gender since the comparison group of patients have lipedema which is a condition predominantly effecting females.
These patient subjects will consist of those who meet the inclusion and exclusion criteria for secondary leg lymphedema and this study requirements.
The intervention in this arm is a course of CDT with graded negative pressure.
|
Complete Decongestive Therapy (CDT)is a common conservative intervention involving stimulation of the lymphatic system, use of compression, skin care and exercise.
The use of graded negative pressure in conjunction with CDT is another conservative therapy intervention used to help clear the lymphatic congestion.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Assessing a Change in Bioimpedance Spectroscopy (BIS) Following CDT with Graded Negative Pressure
Time Frame: At baseline and at 6-8 weeks following the completion of therapy
|
BIS quantified using Impedimed L-dex
|
At baseline and at 6-8 weeks following the completion of therapy
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Assessing a Change in Lymphatic stasis Following CDT with Graded Negative Pressure
Time Frame: At baseline and at 6-8 weeks following the completion of therapy
|
Quantitative analysis of lymphatic stasis using non-invasive MR lymphangiography
|
At baseline and at 6-8 weeks following the completion of therapy
|
Assessing a Change in Limb Volume Following CDT with Graded Negative Pressure
Time Frame: At baseline and at 6-8 weeks following the completion of therapy
|
Volume quantified using Perometer
|
At baseline and at 6-8 weeks following the completion of therapy
|
Assessing a Change in Sodium Levels in Regions of Interest Following CDT with Graded Negative Pressure
Time Frame: At baseline and at 6-8 weeks following the completion of therapy
|
Quantitative analysis of sodium levels using non-invasive sodium MRI
|
At baseline and at 6-8 weeks following the completion of therapy
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Manus J Donahue, PhD, Vanderbilt University Medical Center
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 160199
- LF Award #12 (Other Grant/Funding Number: Lipedema Foundation)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Secondary Lymphedema
-
Tactile MedicalVanderbilt University Medical CenterRecruitingLymphedema | Lymphedema, Secondary | Lymphedema; Surgical | Lymphedema of Face | Lymphedema Due to RadiationUnited States
-
ThuasneUniversity Hospital, Tours; Delta ConsultantsCompletedLymphedema, Secondary | Lymphedema of Leg | Lymphedema Congenital | Lymphedema PrimaryFrance
-
Lymphatica Medtech SATerminatedLymphedema of Upper Limb | Lymphedema, Secondary | Lymphedema, Lower Limb | Lymphedema of Leg | Lymphedema ArmSwitzerland
-
Inland Norway University of Applied SciencesMontebellosenteret, Mesnali, NorwayCompletedLymphedema, SecondaryNorway
-
University Hospital, MontpellierCompletedPrimary Lymphedema Secondary LymphedemaFrance
-
ResMedLymphatic Solutions, LLCCompletedLymphedema | Lymphedema, Secondary | Lymphedema, Lower Limb | Lymphedema of Leg | Lymphedema PrimaryUnited States
-
Our Lady of the Lake HospitalCompletedSecondary Lymphedema | Lymphedema of FaceUnited States
-
Maastricht University Medical CenterRadboud University Medical Center; Erasmus Medical CenterRecruitingLymphedema of Upper Limb | Lymphedema, Secondary | Lymphedema, Lower Limb | Lymphedema of Leg | Lymphedema ArmNetherlands
-
Isabel Forner-Cordero, MD, PhD.CompletedSecondary Lymphedema | Primary LymphedemaSpain
-
Vanderbilt University Medical CenterNational Heart, Lung, and Blood Institute (NHLBI)RecruitingLymphedema, Secondary | Lymphedema of Leg | Lymphedema Related FibrosisUnited States
Clinical Trials on CDT with graded negative pressure
-
Vanderbilt University Medical CenterNational Institute of Nursing Research (NINR); National Institutes of Health...Recruiting
-
SerenaGroup, Inc.Next Science TMCompletedPressure UlcerUnited States
-
University of PittsburghCompletedPulmonary EmbolismUnited States
-
Loma Linda University3M; AcelityRecruiting
-
University of WashingtonNational Center for Advancing Translational Sciences (NCATS)Not yet recruiting
-
Skane University HospitalRecruiting
-
Brno University HospitalMasaryk UniversityRecruitingWeaning FailureCzechia
-
Oslo University HospitalOtivio ASCompletedWound Healing, Leg and Foot Ulcers, Macrocirculation, MicrocirculationNorway
-
Ruhr University of BochumCompletedSoft Tissue Sarcoma | Tumor | LipomaGermany
-
University of DundeeCompleted